To observe the clinical effect of live vaginal Lactobacillus capsule for vaginal use combined with nifuratel nystatin vaginal soft capsule on patients with recurrent vulvovaginal candidiasis (RVVC) and its influence on vaginal microecological environment of patients.

The RVVC patients were divided into the control group and the treatment group according to the cohort method. The patients in the control group were treated with one grain of vaginal embolization before going to bed with nifuratel nystatin vaginal soft capsule. The patients in the treatment group were treated with 0.25 g of vaginal live Lactobacillus capsule in the morning combined with one grain of vaginal embolization before going to bed with nifuratel nystatin vaginal soft capsule. The initial treatment time of the two groups lasted for 7 days. Initial treatment lasted for 7 days in both groups. Pathogenic bacteria culture was performed after 7 days of drug withdrawal. The negative patients were cured, and the cured patients were treated with nifuratel nysfungin vaginal suppository for consolidation treatment once a week for 6 months. The clinical therapeutic effect in the two groups was recorded. The changes in vaginal microecology and human β-defensin (HβD)-3, interleukin (IL)-1β and IL-8 in vaginal secretions were compared between the two groups before treatment and after 7 days of treatment, and the safety evaluation was carried out.

A total of 268 patients were enrolled in this study, including 136 in the treatment group and 132 in the control group. The mycological cure rates of initial treatment in the treatment group and the control group were 84.56% (115 cases/136 cases) and 73.48% (97 cases/132 cases), respectively; the mycological cure rates of consolidation treatment were 82.61% (95 cases/115 cases) and 70.10% (68 cases/97 cases), respectively; the differences were statistically significant (all P<0.05). The proportions of vaginal cleanliness grade Ⅲ-Ⅳ in treatment group and control group after 7 days of treatment were 24.26% and 36.36%; the proportions of vaginal flora density grade Ⅱ-Ⅲ were 79.41% and 68.18%; the proportions of vaginal flora diversity grade Ⅱ-Ⅲ were 77.94% and 65.91%; the proportions of dominant bacteria of Lactobacillus were 82.35% and 68.18%; the levels of HβD-3 in vaginal secretions were (129.65±11.51) and (135.87±10.46) pg·mL^-1; IL-1β levels were (65.48±9.27) and (72.46±10.38) pg·mL^-1; IL-8 levels were (159.36±12.50) and (176.30±13.19) pg·mL^-1 , and the differences were statistically significant (all P<0.05). The total incidence rates of adverse drug reactions in the treatment group and control group were 23.53% (32 cases/136 cases) and 18.38% (25 cases/132 cases), respectively (P>0.05).

Compared with nifuratel nysfungin vaginal soft capsule therapy, the combination of vaginal live Lactobacillus capsule can improve the vaginal microecology of RVVC patients, and the cure rate of vaginal fungal infection is higher, with better safety.

To explore the clinical efficacy and safety of alendronate sodium tablet combined with injection of recombinant teriparatide and calcium carbonate D₃ tablet in the treatment of postmenopausal osteoporosis (PMDP).

The patients with postmenopausal osteoporosis were divided into control group and treatment group according to the cohort method according to the treatment regimen. The control group was treated with calcium carbonate D₃ tablet (600 mg, 1 tablet a day) and alendronate sodium tablet (70 mg, once a week), while the treatment group was given injection of reacombinant teriparatide (200 U/20 μg, 20 μg every day) on the basis of the control group. Both groups were continuously treated for 6 months. The clinical efficacy was compared after 6 months of treatment. The bone mineral density (BMD) of lumbar spine, total hip and femoral neck and levels of bone metabolism indicators [osteocalcin (OCN), tartrate-resistant acid phosphatase-5b (TRAP-5b), procollagen type Ⅰ amino-terminal propeptide (PINP), C-terminal cross-linked peptide of type Ⅰ collagen (CTX-Ⅰ)]before treatment and after 6 months of treatment and bone pain [visual analogue scale (VAS)]and quality of life [European Foundation Osteoporosis Quality of Life Questionnaire (ECOS-16)]before treatment and after 3 and 6 months of treatment were recorded, and the adverse drug reactions within 6 months of treatment were compared.

Fifty-two cases in treatment group and 64 cases in control group were enrolled. After treatment, the total effective rates in treatment group and control group were 87.80% (36 cases/41 cases) and 68.29% (28 cases/41 cases), respectively (P<0.05). The BMD values of lumbar spine in treatment group and control group after treatment were (0.69±0.15) and (0.79±0.18) g·cm^-2; the BMD values of total hip were (0.70±0.11) and (0.77±0.15) g·cm^-2; the BMD values of femoral neck were (0.79±0.19) and (0.87±0.15) g·cm^-2, respectively; the OCN levels were (7.42±1.53) and (5.37±1.16) μg·L^-1; the PINP levels were (85.31±5.66) and (76.30±5.49) ng·mL^-1; the TRAP-5b levels were (3.27±0.46) and (5.16±0.72) U·L^-1; the CTX-I levels were (3.37±0.54) and (5.08±0.70) ng·mL^-1; the VAS scores were (1.48±0.13) and (2.07±0.24) points; the ECOS-16 scores were (24.84±4.62) and (32.71±6.07) points, and there were statistical differences in the above indicators between treatment group and control group (all P<0.05). The main adverse drug reactions in treatment group were rash, dizziness and limb pain, and the main adverse drug reactions in control group were rash, dizziness, nausea, and limb pain, and the total incidence rates of adverse reactions in treatment group and control group were 12.20% (5 cases/41 cases) and 19.51% (8 cases/41 cases) (P>0.05).

Alendronate sodium tablet combined with injection of recombinant teriparatide and calcium carbonate D₃ tablet has a significant short-term efficacy on PMOP patients, and it can help to enhance the bone mineral density, reduce the symptoms of bone pain, and relieve the osteoporosis.

Based on nuclear factor E2 associated factor 2 (NRF2) /PTEN induced hypothesized kinase 1 (PINK1) pathway, explored the ameliorating effect of rutaecarpine on chronic obstructive pulmonary disease (COPD) rats and its repairing effect on airway epithelial barrier.

COPD rat model were established by smoke combined with airway infusion of lipopolysaccharide; and were randomly divided into model group, control group, and experimental -L group, experimental -M group, experimental-H group, 10 rats per group. Another 10 normal rats were selected as the normal group. Experimental -L, -M, -H groups were intraperitoneally injected 15, 30 and 60 mg·mL^-1 rutaecarpine at the dose of 10 mL·kg^-1, respectively. The control group was received 4.05×10^-2 mg·mL^-1 prednisone acetate at the dose of 10 mL·kg^-1 by gavage. The normal and model groups were given 0.9% NaCl by intraperitoneal injection. Six groups were treated for 28 days with once a day. The first second forced expiratory volume (FEV1) and forced vital capacity (FVC) of rats were measured by minor animal lung function tester. The levels of interleukin (IL) and interferon-γ (INF-γ) in alveolar lavage fluid were determined by enzyme-linked immunosorbent assay method. The expression levels of PINK1 and NRF2 proteins in the lung tissue were determined by Western blot.

The levels of FEV1 in the experimental -M group, experimental -H group, control group, model group and normal group were (5.17±0.16), (6.36±0.12), (5.06±0.07), (2.24±0.20) and (6.84±0.11) mL; the levels of FVC were (6.71±0.13), (7.56±0.12), (6.81±0.07), (4.46±0.14) and (7.92±0.11) mL; the levels of IL-12 in alveolar lavage fluid were (7.08±0.51), (9.03±0.54), (7.92±0.79), (3.61±1.01) and (10.15±0.82) pg·mL^-1; the levels of IL-9 in alveolar lavage fluid were (22.49±2.27), (15.02±1.41), (17.47±1.84), (38.72±1.28) and (11.78±0.94) pg·mL^-1; the levels of INF-γ in alveolar lavage fluid were (13.18±0.54), (16.25±0.60), (15.23±0.43), (6.97±0.89) and (17.22±1.15) pg·mL^-1; the relative expression levels of PINK1 protein were 1.10±0.06, 1.30±0.09, 1.18±0.15, 0.42±0.03 and 1.61±0.05; the relative expression levels of NRF2 protein were 0.91±0.05, 1.46±0.03, 1.35±0.07, 0.53±0.07 and 1.64±0.11, respectively. The differences of above indexes were statistically significant between the experimental -M group, experimental -H group, control group and the model group (all P<0.05).

Rutaecarpine can inhibit inflammation, improve lung function and repair airway epithelial barrier in COPD rats, and its mechanism may be related to regulating NRF2/PINK1 pathway.